Search clinical trials for: MLF 541

Total 4538 results

B. Braun Melsungen AG
B.Braun Taiwan Co., Ltd.

Completed

Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery

GI Cancer

Taiwan
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Leukemia | Chronic Myeloproliferative Disorders

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Sarcoma | Brain and Central Nervous System Tumors | Gastrointestinal Stromal Tumor

United States
Campus Bio-Medico University
University of Rome Tor Vergata; University Hospital of Ferrara; Arcispedale Santa... and other collaborators

Terminated

Low-frequency Pulsed Electromagnetic Fields (ELF-MF) as Treatment for Acute Ischemic Stroke (I-NIC)

Ischemic Stroke | Stroke, Acute

Italy
Campus Bio-Medico University

Unknown

Extremely Low Frequency Magnetic Fields in Acute Ischemic Stroke

Stroke

Italy
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

Healthy

Australia
Erchonia Corporation

Completed

Study of Low Level Laser Therapy for Body Contouring

Body Contouring

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)

Type 2 Diabetes Mellitus

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150 (CKD-383)

Type 2 Diabetes

Korea, Republic of
Erchonia Corporation

Terminated

Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers

Venous Stasis Ulcer

United States, France
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Autonomous University of Morelos
Instituto Mexicano del Seguro Social; Universidad Autonoma de Nuevo Leon

Completed

Open Multi-center Safety & Efficacy Study of Low Frequency Magnetic Fields to Treat Unresponsive Diabetic Foot Ulcers.

Neuropathic Diabetic Ulcer - Foot

Mexico
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Ludwig-Maximilians - University of Munich

Completed

Development a Method to Extract Antibiotic Concentration From Interstitial Lung and Epithelial Lining Fluid. (ALF)

Lung Transplantation

Germany
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Breast Cancer

United States
Bellicum Pharmaceuticals

Active, not recruiting

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Terminated

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, South Africa
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

Healthy Volunteers

United States
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
JCR Pharmaceuticals Co., Ltd.

Recruiting

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Mucopolysaccharidosis II

United States, Germany, Spain, France, Brazil, Argentina, Turkey, United Kingdom, Poland, Italy
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Advanced Prostate Cancer

China
Ezra Cohen
The V Foundation for Cancer Research

Recruiting

Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | HPV-Related Malignancy | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | HPV-Related Carcinoma | HPV-Related Squamous Cell Carcinoma | Head and Neck Cancer Stage IV | Head and Neck Cancer Stage III

United States
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II

Brazil
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Concert Pharmaceuticals

Completed

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Health Volunteers

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Abbott Medical Devices

Completed

AVJ-514 Japan Trial

Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With Insufficiency

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

Acute Myeloid Leukemia

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

Cystitis, Interstitial

United States, Austria, Germany
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Alkermes, Inc.

Completed

A Water Consumption Study of ALKS 5461 in Healthy Volunteers

Healthy

United States
MedImmune LLC

Terminated

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors (MEDI-547)

Cancer

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males

Alzheimer Disease
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

Healthy

Japan
TetraLogic Pharmaceuticals
PPD; The Leukemia and Lymphoma Society; Veristat, Inc.; Therapeutics, Inc.

Completed

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Lymphoma, T-Cell, Cutaneous

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Pain

United States
Amicus Therapeutics

Active, not recruiting

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

Batten Disease | CLN6

United States
Amgen

Completed

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura
Chong Kun Dang Pharmaceutical

Completed

Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects

Healthy | Renal Impairment

Korea, Republic of
MedImmune LLC

Completed

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Scleroderma

United States, United Kingdom, Canada
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

Alzheimer Disease

France
Concert Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada

Search clinical trials for: MLF 541

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations